Controlled delivery formulations remain one of the favored tools for advancing the lifecycle of pharmaceutical products, and excipient selection is vitally important. A traditional strategy is to initially launch multiple daily doses of an immediate-release (IR) product, then reformulate into a once-daily modified-release product, simplifying dosing regimens while retaining efficacy and potentially improving its safety profile.Further, excipients have become major research components in the pharmaceutical industry. Controlled release excipients give the formulator the ability to carry APIs to a targeted location in the body. This benefit increases the product’s bioavailability and minimizes side effects. With the correct excipient, formulators can control when, where, and how an API is released.
Excipient Selection Challenges
Given the lack of an approval pathway, many drug developers are hesitant to take on the responsibility of toxicology and clinical trials with a untested materials, which may run risk jeopardizing approval of their new drug applications. Additionally, for certain patient populations, excipient choices are somewhat limited. However, there has been a growth in excipient suppliers developing novel excipients that may provide solutions and support to move existing formulations into new areas.
Rational Excipient Selection & Collaboration
Many new excipients are modifications or combinations of previously approved excipients. Excipient selection for the formulation for an immediate release tablet is typically guided by a number of critical attributes of the active ingredient, including concentration, compactability, and solubility.
Excipient manufacturers are working closer with drug product manufacturers as early as possible in the drug product development process in order to not only identify the issues, but to mitigate the impact of the issues proactively. The most successful controlled release formulation approaches have been where excipient suppliers have worked side-by-side with drug developers to understand their specific needs, and, over time, have developed new solutions to meet controlled release formulation challenges as they have arisen.
The question you must ask yourselves and your organization is can you afford not to develop these products from a lifecycle management standpoint? Want to Learn More?
Our goal is to help you improve the performance of your drug products. Would you like to learn new strategies to improve patient compliance, bioavailability, stability and efficacy, all while reducing dosage, cost and decreasing time-to-market?
Don’t miss your opportunity to join industry’s leading drug development innovators and experts at the 2021 Controlled & Modified Drug Release (CR7) & 2021 Peptide Drug Design & Delivery (PEP5) Summits, and walk away with 2 years worth of new product development strategies in just 3 days!
This industry-leading event will bring together key decision makers and innovators within this rapidly growing space. By attending this unique event, you will learn directly from industry’s leading experts and hear unique case study sessions and take-home examples to enhance your product pipeline. Gather insights into the latest technologies and methods in improving drug release mechanisms, maximizing exposure, and reducing time-to-market. Additionally, this must-attend event will showcase the latest regulatory guidance updates and the implications for the industry.
Why consider attending the CR7 & PEP5 Summits?
- 60+ leading industry-led speaker faculty over 3 full days sharing innovative drug development take-home strategies
- 14+ hours of networking and breakout sessions, including evening cocktail reception
- 160+ senior participants senior participants spanning pharma, biotech and specialty delivery and formulation providers
- 2 Events for the Price of 1! Attendees gain access to both events and all networking receptions / tech showcase exhibits for one registration. Group discounts available also!
- Dynamic exhibit hall with multiple leading formulation and drug delivery technology experts
Join over 1250 senior drug product development professionals in our free Novel Drug Discovery & Development Group. Members of this rapidly growing group will benefit by gaining access to an exclusive network of industry and academic professionals within the drug development arena. Members specialize in discovery, development, formulation, delivery and commercialization of innovative drug products.
Want to hear multiple weekly drug product development strategies and approaches from leading organizations and experts? Subscribe here and receive new podcast episodes, presentations, white papers, tips and resources directly from Curtis & Coulter weekly to your inbox